Contributions
Abstract: EP1586
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 24 Neuropsychology
Background: Cognitive and affective dysfunction negatively impact daily living of patients, particularly quality of life (QoL). Pharmacological treatment did not demonstrate any effect on cognition compared to cognitive rehabilitation (CR) programs that show promising results but are less consistent concerning affective and QoL domains.
Objective: We developed a randomized controlled study to demonstrate the interest of a patient's tailored computerized CR program, conducted at home, on QoL and self-esteem (SE).
Methods: This project comprises two phases. First, we conducted a pilot study on 10 multiple sclerosis (MS) patients to assess the feasibility and acceptance of this project. 41 computerized exercises were further selected according to the specificity of MS cognitive difficulties and appropriate recommendations of patients. The second step will consist of the randomized study conducted with two groups (the experimental group and the control group). The experimental group will benefit for the CR program and a psychological support at home during eight weeks (3 sessions exercises of 45 minutes per week) whereas the control group will only receive psychological support. QoL and SE, respectively assessed by the MUSIQOL and the SE-inventory questionnaires, will be evaluated three times (at baseline, after the CR program and 6 months after the CR program). Given the expected MUSIQOL score variation, inclusion of 18 patients per group will be required.
Results: Pilot-study showed high acceptance and feasibility of exercises as well as improved subjective QoL. Preliminary results of the randomized study will be presented at the meeting.
Conclusion: As QoL and SE are poorly evaluated in CR studies, we believe that this original customizeed CR program will highlight the benefits on both parameters over short and longer delays in patient's daily life.
Disclosure: C. Harand: nothing to disclose
F. Daniel: nothing to disclose
A. Mondou: nothing to disclose
D. Chevanne: nothing to disclose
P. Branger received funding for speaker honoraria from Novartis and Sanofi-Genzyme.
N. Derache received funding for speaker honoraria from Merck-Serono, Biogen-Idec, Novartis, Teva and Sanofi-Genzyme.
G. Defer received personal compensation for serving on scientific advisory boards for Biogen Idec, Merck-Serono, Novartis, Sanofi Aventis, Genzyme and Teva Pharmaceutical Industries Ltd. He has received funding for travel and/or speaker honoraria from Merck Serono, Biogen, Guerbet, Sanofi Aventis, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd. His institution received grants supporting research in his department from Merck Serono, Biogen, Sanofi Aventis and Novartis.
Abstract: EP1586
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 24 Neuropsychology
Background: Cognitive and affective dysfunction negatively impact daily living of patients, particularly quality of life (QoL). Pharmacological treatment did not demonstrate any effect on cognition compared to cognitive rehabilitation (CR) programs that show promising results but are less consistent concerning affective and QoL domains.
Objective: We developed a randomized controlled study to demonstrate the interest of a patient's tailored computerized CR program, conducted at home, on QoL and self-esteem (SE).
Methods: This project comprises two phases. First, we conducted a pilot study on 10 multiple sclerosis (MS) patients to assess the feasibility and acceptance of this project. 41 computerized exercises were further selected according to the specificity of MS cognitive difficulties and appropriate recommendations of patients. The second step will consist of the randomized study conducted with two groups (the experimental group and the control group). The experimental group will benefit for the CR program and a psychological support at home during eight weeks (3 sessions exercises of 45 minutes per week) whereas the control group will only receive psychological support. QoL and SE, respectively assessed by the MUSIQOL and the SE-inventory questionnaires, will be evaluated three times (at baseline, after the CR program and 6 months after the CR program). Given the expected MUSIQOL score variation, inclusion of 18 patients per group will be required.
Results: Pilot-study showed high acceptance and feasibility of exercises as well as improved subjective QoL. Preliminary results of the randomized study will be presented at the meeting.
Conclusion: As QoL and SE are poorly evaluated in CR studies, we believe that this original customizeed CR program will highlight the benefits on both parameters over short and longer delays in patient's daily life.
Disclosure: C. Harand: nothing to disclose
F. Daniel: nothing to disclose
A. Mondou: nothing to disclose
D. Chevanne: nothing to disclose
P. Branger received funding for speaker honoraria from Novartis and Sanofi-Genzyme.
N. Derache received funding for speaker honoraria from Merck-Serono, Biogen-Idec, Novartis, Teva and Sanofi-Genzyme.
G. Defer received personal compensation for serving on scientific advisory boards for Biogen Idec, Merck-Serono, Novartis, Sanofi Aventis, Genzyme and Teva Pharmaceutical Industries Ltd. He has received funding for travel and/or speaker honoraria from Merck Serono, Biogen, Guerbet, Sanofi Aventis, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd. His institution received grants supporting research in his department from Merck Serono, Biogen, Sanofi Aventis and Novartis.